These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 22508827

  • 1. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.
    Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C.
    J Clin Oncol; 2012 Jun 01; 30(16):1996-2004. PubMed ID: 22508827
    [Abstract] [Full Text] [Related]

  • 2. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.
    Breast Cancer Res Treat; 2012 Feb 01; 131(3):827-36. PubMed ID: 21472434
    [Abstract] [Full Text] [Related]

  • 3. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 4. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G.
    Ann Surg Oncol; 2011 Oct 15; 18(11):3149-54. PubMed ID: 21947592
    [Abstract] [Full Text] [Related]

  • 5. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
    Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E.
    Eur J Cancer; 2012 Dec 15; 48(18):3342-54. PubMed ID: 22766518
    [Abstract] [Full Text] [Related]

  • 6. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.
    Cancer Chemother Pharmacol; 2012 Feb 15; 69(2):533-46. PubMed ID: 21901395
    [Abstract] [Full Text] [Related]

  • 7. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L.
    Cancer Res; 2010 Nov 01; 70(21):8852-62. PubMed ID: 20959472
    [Abstract] [Full Text] [Related]

  • 8. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.
    J Clin Oncol; 2010 Apr 10; 28(11):1813-20. PubMed ID: 20231686
    [Abstract] [Full Text] [Related]

  • 9. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L.
    Breast Cancer Res Treat; 2008 Mar 10; 108(2):183-90. PubMed ID: 17468948
    [Abstract] [Full Text] [Related]

  • 10. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.
    von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P.
    Breast Cancer Res Treat; 2011 Jan 10; 125(1):145-56. PubMed ID: 21042932
    [Abstract] [Full Text] [Related]

  • 11. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM, Lowe KA, Atwood M, Beatty JD.
    Breast J; 2010 Jan 10; 16(4):362-8. PubMed ID: 20443786
    [Abstract] [Full Text] [Related]

  • 12. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct 10; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 13. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C, Dettwiler S, Beuzeboc P, Alran S, Laurence V, Pierga JY, Fréneaux P, Sigal-Zafrani B, Diéras V, Vincent-Salomon A.
    Am J Clin Oncol; 2012 Jun 10; 35(3):242-6. PubMed ID: 21358298
    [Abstract] [Full Text] [Related]

  • 14. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G, Loibl S, Maisch A, Untch M.
    Breast; 2011 Oct 10; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [Abstract] [Full Text] [Related]

  • 15. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.
    Breast; 2013 Oct 10; 22(5):691-7. PubMed ID: 23414930
    [Abstract] [Full Text] [Related]

  • 16. [Analysis of associations between molecular subtypes and responses to neoadjuvant chemotherapy in primary breast cancer patients].
    Zhou YJ, Ying M, He YJ, Liu YQ, Fan ZQ, Fan T, Li JF, Wang TF, Xie YT, Lu AP, Ouyang T.
    Zhonghua Yi Xue Za Zhi; 2013 Jun 11; 93(22):1711-5. PubMed ID: 24124677
    [Abstract] [Full Text] [Related]

  • 17. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.
    Zentralbl Gynakol; 2006 Apr 11; 128(2):76-81. PubMed ID: 16673249
    [Abstract] [Full Text] [Related]

  • 18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 11; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 19. Genomics of adjuvant therapy for breast cancer.
    Kim SR, Paik S.
    Cancer J; 2011 Jul 11; 17(6):500-4. PubMed ID: 22157294
    [Abstract] [Full Text] [Related]

  • 20. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S.
    Breast Cancer Res Treat; 2010 Jan 11; 119(1):119-26. PubMed ID: 19669409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.